Table 1.
Relative expression of APPs in the sera of patients in different clinical stages of EOCa.
| Serum proteins | *Fold changes and statistical significance | Probability P | |||
| Stage I | Stage II | Stage III | Stage IV | ||
| CLU | # | # | nd | nd | 0.0004 |
| LRG | +23.36-fold; p = 0.0001 |
+16.46-fold; p = 0.0001 |
+6.44-fold; p = 0.0001 |
+15.34-fold; p = 0.0128 |
0.0001 |
| ACT | +2.65-fold; p = 0.0001 |
+3.94-fold; p = 0.0006 |
+5.50-fold; p = 0.0001 |
ns | 0.2177 |
| HAP | +2.24-fold; p = 0.0001 |
+2.84-fold; p = 0.0004 |
+6.78-fold; p = 0.0001 |
ns | 0.0001 |
| AAT | +2.52-fold;p = 0.0001 | +3.35-fold;p = 0.0001 | +4.09-fold;p = 0.0001 | +4.75-fold;p = 0.0001 | 0.0008 |
| HAPc | # | # | # | # | 0.0757 |
| AATf | +7.30-fold; p = 0.0001 |
+8.91-fold; p = 0.0001 |
+8.12-fold; p = 0.0001 |
+14.14-fold; p = 0.0001 |
0.0388 |
*Fold change measures the degree of change in protein expression in patients compared to that of negative controls. This is measured by dividing the average spot intensity in the patients by average spot intensity in the control.
# exclusive detection in patients (not detected in negative controls)
ns protein not significantly expressed
nd protein not detected
+ increased in expression
-- decreased in expression